Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA decreased its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 7.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 425,232 shares of the company’s stock after selling 33,072 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Kiniksa Pharmaceuticals International were worth $17,541,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of KNSA. Rubric Capital Management LP raised its stake in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after purchasing an additional 90,194 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after purchasing an additional 332,846 shares in the last quarter. Qube Research & Technologies Ltd raised its stake in shares of Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 8.7% during the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Kiniksa Pharmaceuticals International by 16.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 725,355 shares of the company’s stock valued at $28,166,000 after purchasing an additional 101,666 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Trading Down 1.2%

Shares of Kiniksa Pharmaceuticals International stock opened at $45.32 on Friday. The company’s 50-day moving average price is $46.15 and its two-hundred day moving average price is $42.56. Kiniksa Pharmaceuticals International, plc has a 52 week low of $19.62 and a 52 week high of $50.03. The stock has a market cap of $3.47 billion, a PE ratio of 61.24 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The business had revenue of $202.13 million during the quarter, compared to the consensus estimate of $200.86 million. During the same quarter last year, the firm posted ($0.12) earnings per share. Kiniksa Pharmaceuticals International’s revenue was up 65.0% compared to the same quarter last year. On average, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 6,625 shares of the business’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $46.69, for a total value of $309,321.25. Following the sale, the chief accounting officer directly owned 27,418 shares in the company, valued at approximately $1,280,146.42. The trade was a 19.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 7,278 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $50.01, for a total transaction of $363,972.78. Following the completion of the sale, the chief executive officer owned 7,278 shares in the company, valued at approximately $363,972.78. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,479 shares of company stock valued at $2,832,812 in the last quarter. 53.48% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective on the stock. Finally, Wedbush lifted their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $58.00 and gave the company an “outperform” rating in a research note on Thursday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and an average price target of $56.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.